Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer

Head and Neck

Volumn 36, Issue 12, 2014, Pages 1747-1753

  Campian, Jian L ^a   Sarai, Guneet ^b   Ye, Xiaobu ^a   Marur, Shanthi ^a   Grossman, Stuart A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

Chemotherapy; Head and neck squamous cell carcinoma; Lymphopenia; Radiation; Treatment related toxicities

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELLULITIS; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIMODALITY CANCER THERAPY; POSTOPERATIVE INFECTION; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; WART VIRUS; ADVERSE EFFECTS; BLOOD; CARCINOMA, SQUAMOUS CELL; DISEASE FREE SURVIVAL; HEAD AND NECK NEOPLASMS; LYMPHOPENIA; MIDDLE AGED; MORTALITY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOCYTE COUNT; LYMPHOPENIA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84912052604     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23535     Document Type: Article

References (29)

1. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480: 480-489.
2. Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival. Cancer 2010;116: 1767-1775.
3. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363: 411-422.
4. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012;104: 273-279.
5. Lissoni P, Brivio F, Fumagalli L, et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004;19: 135-140.
6. Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 2009;69: 5383-5391.
7. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD81 T cells and CD41 T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94: 275-280.
8. Lohr J, Ratliff T, Huppertz A, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-ß. Clin Cancer Res 2011;17: 4296-4308.
9. Dahlin AM, Henriksson ML, Van Guelpen B, et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol 2011;24: 671-682.
10. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117: 1137-1146.
11. Wolf GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: Correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg 1986;95: 142-152.
12. Whiteside TL, Chikamatsu K, Nagashima S, Okada K. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer. Anticancer Res 1996;16: 2357-2364.
13. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10: 3755-3762.
14. Wolf GT, Schmaltz S, Hudson J, et al. Alterations in T-lymphocyte subpopulations in patients with head and neck cancer. Correlations with prognosis. Arch Otolaryngol Head Neck Surg 1987;113: 1200-1206.
15. Balmanoukian A, Ye X, Herman J, Laheru D, Grossman SA. The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Invest 2012;30: 571-576.
16. Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 2011;17: 5473-5480.
17. Campian JL, Ye X, Brock M, Grossman SA. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest 2013;31: 183-188.
18. Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: Modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest 2013;31: 140-144.
19. De Castro G Jr, Pasini FS, Siqueira SA, et al. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep 2011;25: 693-699.
20. Kokemueller H, Brachvogel P, Eckardt A, Hausamen JE. Neck dissection in oral cancer-clinical review and analysis of prognostic factors. Int J Oral Maxillofac Surg 2002;31: 608-614.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-481.
22. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38: 29-41.
23. Nordman E, Toivanen A. Effects of irradiation on the immune function in patients with mammary, pulmonary or head and neck carcinoma. Acta Radiol Oncol Radiat Phys Biol 1978;17: 3-9.
24. Gray WC, Chretien PB, Suter CM, et al. Effects of radiation therapy on T-lymphocyte subpopulations in patients with head and neck cancer. Otolaryngol Head Neck Surg 1985;93: 650-660.
25. Stratton JA, Byfield PE, Byfield JE, Small RC, Benfield J, Pilch Y. A comparison of the acute effects of radiation therapy, including or excluding the thymus, on the lymphocyte subpopulations of cancer patients. J Clin Invest 1975;56: 88-97.
26. Tisch M, Heimlich F, Daniel V, Opelz G, Maier H. Cellular immune defect caused by postsurgical radiation therapy in patients with head and neck cancer. Otolaryngol Head Neck Surg 1998;119: 412-417.
27. Yang SJ, Rafla S, Youssef E, Selim H, Salloum N, Chuang JY. Changes in T-cell subsets after radiation therapy. Radiology 1988;168: 537-540.
28. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8: 1765-1780.
29. Verastegui EL, Morales RB, Barrera-Franco JL, Poitevin AC, Hadden J. Long-term immune dysfunction after radiotherapy to the head and neck area. Int Immunopharmacol 2003;3: 1093-1104.